This Insider Has Just Sold Shares In Janux Therapeutics

We wouldn't blame Janux Therapeutics, Inc. (NASDAQ:JANX) shareholders if they were a little worried about the fact that Tighe Reardon, a company insider, recently netted about US$1.8m selling shares at an average price of US$51.81. That sale reduced their total holding by 26% which is hardly insignificant, but far from the worst we've seen.

Check out our latest analysis for Janux Therapeutics

Janux Therapeutics Insider Transactions Over The Last Year

In fact, the recent sale by Tighe Reardon was the biggest sale of Janux Therapeutics shares made by an insider individual in the last twelve months, according to our records. That means that an insider was selling shares at below the current price (US$53.41). We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. However, while insider selling is sometimes discouraging, it's only a weak signal. We note that the biggest single sale was only 26% of Tighe Reardon's holding.

In the last year Janux Therapeutics insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

Insider Ownership Of Janux Therapeutics

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Janux Therapeutics insiders own 9.7% of the company, currently worth about US$269m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

What Might The Insider Transactions At Janux Therapeutics Tell Us?

Insiders sold Janux Therapeutics shares recently, but they didn't buy any. And there weren't any purchases to give us comfort, over the last year. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we've found that Janux Therapeutics has 4 warning signs (1 is potentially serious!) that deserve your attention before going any further with your analysis.

Of course Janux Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.